TY - JOUR
T1 - Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I)
T2 - Minimum requirements and beyond
AU - Pasquini, Marcelo C.
AU - Srivastava, Alok
AU - Ahmed, Syed Osman
AU - Aljurf, Mahmoud
AU - Atsuta, Yoshiko
AU - Doleysh, Carol
AU - Galeano, Sebastian
AU - Gluckman, Eliane
AU - Greinix, Hildegard
AU - Hale, Gregory
AU - Hari, Parameswaran
AU - Hashmi, Shahrukh K.
AU - Kamani, Naynesh
AU - Laughlin, Mary J.
AU - Niederwieser, Dietger
AU - Seber, Adriana
AU - Szer, Jeffrey
AU - Snowden, John A.
AU - Van Biesen, Koen
AU - Watry, Paula
AU - Weisdorf, Daniel J.
AU - Apperley, Jane
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2020/9
Y1 - 2020/9
N2 - Hematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize its safety. In addition, institutions may have different needs regarding indications based on regional disease prevalence or may have an interest in developing specialized services. Yet, structured recommendations are not commonly available. Here, the Transplant Center and Recipient Issues Standing Committee for the Worldwide Network for Blood and Marrow Transplantation (WBMT) organized a structured review of all pertinent elements to establish a transplant program. First, we solicited components from committee members and grouped them in domains (infrastructure, staff, cell processing laboratory, blood banking, laboratory, radiology, pharmacy, HLA testing, ancillary services and quality). Subsequently, reviewers scored all elements on a 7-point scale, from an absolute requirement (score of 1) to not required (score of 7). An independent group of five experienced transplant physicians reviewed the rankings. Minimum requirements to establish any HCT program were identified among elements with mean score of ≤2.0, and specific elements for allogeneic and autologous HCT were identified. Mean scores >2.0–4.0 were classified as preferred recommendation, and mean scores of >4.0 to ≤7.0 were considered ideal recommendations for advanced and complex types of transplantation. This structured set of recommendations guides the prioritization of minimum requirements to establish a transplant program and to set the path for expansion and further development.
AB - Hematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize its safety. In addition, institutions may have different needs regarding indications based on regional disease prevalence or may have an interest in developing specialized services. Yet, structured recommendations are not commonly available. Here, the Transplant Center and Recipient Issues Standing Committee for the Worldwide Network for Blood and Marrow Transplantation (WBMT) organized a structured review of all pertinent elements to establish a transplant program. First, we solicited components from committee members and grouped them in domains (infrastructure, staff, cell processing laboratory, blood banking, laboratory, radiology, pharmacy, HLA testing, ancillary services and quality). Subsequently, reviewers scored all elements on a 7-point scale, from an absolute requirement (score of 1) to not required (score of 7). An independent group of five experienced transplant physicians reviewed the rankings. Minimum requirements to establish any HCT program were identified among elements with mean score of ≤2.0, and specific elements for allogeneic and autologous HCT were identified. Mean scores >2.0–4.0 were classified as preferred recommendation, and mean scores of >4.0 to ≤7.0 were considered ideal recommendations for advanced and complex types of transplantation. This structured set of recommendations guides the prioritization of minimum requirements to establish a transplant program and to set the path for expansion and further development.
KW - Autologous vs. allogeneic transplants
KW - Transplant program requirements
UR - http://www.scopus.com/inward/record.url?scp=85071270497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071270497&partnerID=8YFLogxK
U2 - 10.1016/j.hemonc.2019.08.001
DO - 10.1016/j.hemonc.2019.08.001
M3 - Article
C2 - 31449780
AN - SCOPUS:85071270497
SN - 1658-3876
VL - 13
SP - 131
EP - 142
JO - Hematology/ Oncology and Stem Cell Therapy
JF - Hematology/ Oncology and Stem Cell Therapy
IS - 3
ER -